Fractyl Health, Inc. (GUTS)
0.7239
-0.01
(-1.08%)
USD |
NASDAQ |
Jun 11, 16:00
0.7355
+0.01
(+1.60%)
After-Hours: 20:00
Fractyl Health Debt to Equity Ratio : 2.845 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 2.845 |
| December 31, 2025 | 6.518 |
| September 30, 2025 | -19.57 |
| June 30, 2025 | -3.389 |
| March 31, 2025 | 9.635 |
| December 31, 2024 | 2.199 |
| September 30, 2024 | 1.251 |
| June 30, 2024 | 0.8653 |
| March 31, 2024 | 0.7191 |
| Date | Value |
|---|---|
| December 31, 2023 | -1.150 |
| September 30, 2023 | -1.116 |
| June 30, 2023 | -1.110 |
| March 31, 2023 | |
| December 31, 2022 | -1.216 |
| September 30, 2022 | |
| December 31, 2021 | -1.454 |
| September 30, 2021 | -1.543 |
| December 31, 2020 | -1.174 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Co-Diagnostics, Inc. | 0.1266 |
| Spectral AI, Inc. | -1.128 |
| Replimune Group, Inc. | 0.3626 |
| Lantern Pharma, Inc. | 0.0172 |
| Arrowhead Pharmaceuticals, Inc. | 2.237 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 99.38M |
| Total Liabilities (Quarterly) | 78.01M |
| Shareholders Equity (Quarterly) | 21.38M |
| Current Ratio | 4.278 |
| Net Debt Paydown Yield | 0.46% |